The coronavirus pandemic has brought to light a new autoinflammatory condition that affects children: the paediatric multisystem inflammatory syndrome (PIMS). Pr Alexandre Belot, paediatric rheumatologist, tells us more about the symptoms of this disease, the treatments and the protective effect of vaccination on this pathology.

IMMUNAID, The European project willing to identify biomarkers for the diagnosis of rare systemic autoinflammatory diseases, has just opened clinical sites in Belgium, Switzerland and in the UK, reaching more than half of the full recruitment capacity.

The NLRP3 inflammasome is the most thoroughly studied of the inflammasomes, and represents a valuable target in the clinical evaluation and treatment of systemic autoinflammatory diseases (SAIDs). We’ve summarised the rapidly progressing field of NLRP3 inflammasome regulation and its wider implications, both in the laboratory and in the clinic.

Now the number of COVID-19 patients has reduced significantly, the hospitals can again focus on their core activities. Already activated sites are able to recruit patients again and new sites are being opened.

An intriguing elevated number of Kawasaki disease cases, a rare inflammatory disorder, are recently noticed. The current pandemic context clearly questions a possible link between the SARS-CoV-2 virus, and the Kawasaki disease phenotype.